See the DrugPatentWatch profile for Yutiq
Yutiq (pralsetinib) is a specialty oncology drug approved for RET‑fusion–positive non‑small cell lung cancer (NSCLC) and ROS1‑positive NSCLC. Because it’s a highly specialized, investigational‑like therapy, its price is substantial and can vary considerably depending on the country, insurer, and any negotiated discounts or assistance programs.
| Region | Typical U.S. List Price | Typical U.S. Annual Cost | Notes |
|--------|------------------------|--------------------------|-------|
| United States | ≈ $20–$25 k per month (≈ $240–$300 k per year) | $240–$300 k per year | List price (average wholesale price, AWV). Actual out‑of‑pocket costs can be much lower if insurance covers the drug or if a manufacturer discount is applied. |
| Canada | List price ≈ $17–$20 k CAD per month (≈ $200–$240 k CAD per year) | $200–$240 k CAD per year | Many provincial formularies negotiate a lower price; the cost to a patient varies. |
| European Union (generic estimate) | €18–€23 k per month (≈ €216–€276 k per year) | €216–€276 k per year | Prices differ by member state and payer; many national health systems negotiate discounts. |
| Australia | AUD 15–20 k per month (≈ AUD 180–240 k per year) | AUD 180–240 k per year | Medicare or private insurer may cover a portion, with patient co‑payment required. |
Key points to keep in mind
1. List price ≠ what you pay.
- Most patients are covered by commercial or public insurance.
- Manufacturers often provide confidential discounts or “real‑world” prices that can be 30–60 % below the list price.
- The manufacturer (Pfizer) offers a Patient Assistance Program (PAP) for those who qualify—this can cover copays, coinsurance, and sometimes the full drug cost.
- Pharmacy benefit managers (PBMs) and insurers may negotiate further reductions, especially for high‑cost oncology drugs.
2. Insurance coverage & prior authorization
- Because Yutiq is a new and highly specialized agent, insurers usually require prior authorization.
- Coverage decisions often consider whether the patient has a confirmed RET‑fusion or ROS1‑positive tumor, and whether prior lines of therapy have been exhausted.
3. Generic and biosimilar status
- No generic version of pralsetinib is currently approved; it remains a brand‑name drug.
- As it ages and patent protections expire, a generic or lower‑cost alternative may enter the market, potentially lowering prices.
4. Where to get the most accurate cost
- Pharmacy: Ask your pharmacist for the net price after insurance and discount.
- Insurance: Contact your plan’s member services for a cost‑estimation tool or to confirm coverage.
- Patient assistance: Visit Pfizer’s Yutiq support page or call the program directly.
5. Other financial assistance
- Many oncology centers offer a financial‑navigation service to help patients explore grants, clinical‑trial enrollment (sometimes with free drug), and community‑based aid.
Quick steps if you’re considering Yutiq
1. Confirm diagnosis – a verified RET‑fusion or ROS1‑positive tumor is required.
2. Check coverage – call your insurer for prior‑authorization requirements.
3. Ask about discounts – pharmacists and the insurer can tell you whether a discount is available.
4. Explore assistance – apply to Pfizer’s Patient Assistance Program if you’re eligible.
5. Track the cost – keep a record of copays, coinsurance, and any out‑of‑pocket payments; this helps with budgeting and future claims.
---
Bottom line
- List price: roughly $20–$25 k/month in the U.S.
- Actual out‑of‑pocket: often much lower, especially if you have insurance coverage and/or qualify for a manufacturer assistance program.
- Check with your provider and insurer for the most accurate, up‑to‑date cost for your situation.